Arvinas to Present at the 2020 Wedbush PacGrow Virtual Healthcare Conference
August 07 2020 - 7:00AM
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology
company creating a new class of drugs based on targeted protein
degradation, today announced that Ron Peck, M.D., Chief
Medical Officer, will participate in a fireside chat at the 2020
Wedbush PacGrow Virtual Healthcare Conference on Tuesday,
August 11 at 10:20 a.m. ET.
A live audio webcast of the presentation will be available here
and on the Company’s website at www.arvinas.com. A replay of the
webcast will be archived on the Arvinas website for 30 days
following the presentation.
About Arvinas Arvinas is a clinical-stage
biopharmaceutical company dedicated to improving the lives of
patients suffering from debilitating and life-threatening diseases
through the discovery, development, and commercialization of
therapies that degrade disease-causing proteins. Arvinas uses its
proprietary technology platform to engineer proteolysis targeting
chimeras, or PROTAC® targeted protein degraders, that are designed
to harness the body’s own natural protein disposal system to
selectively and efficiently degrade and remove disease-causing
proteins. The company has two clinical-stage programs: ARV-110 for
the treatment of men with metastatic castrate-resistant prostate
cancer; and ARV-471 for the treatment of patients with locally
advanced or metastatic ER+/HER2- breast cancer. For more
information, visit www.arvinas.com.
Contacts for Arvinas
InvestorsWill O’Connor, Stern Investor Relations
ir@arvinas.com
MediaKirsten Owens, Arvinas
Communicationskirsten.owens@arvinas.com
Arvinas (NASDAQ:ARVN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arvinas (NASDAQ:ARVN)
Historical Stock Chart
From Apr 2023 to Apr 2024